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Dendritic cells (DCs) modulate B-cell diﬀerentiation, activation, and survival mainly through production of growth factors such
as B lymphocyte stimulator (BLyS/BAFF). DC populations have been reported to be aﬀected in number, phenotype and function
during HIV infection and such alterations may contribute to the dysregulation of the B-cell compartment. Herein, we reﬂect on
the potential impact of DC on the pathogenesis of HIV-related B cell disorders, and how DC status may modulate the outcome
of mucosal B cell responses against HIV, which are pivotal to the control of disease. A concept that could be extrapolated to the
overall outcome of HIV disease, whereby control versus progression may reside in the host’s capacity to maintain DC homeostasis
at mucosal sites, where DC populations present an inherent capacity of modulating the balance between tolerance and protection,
and are amongst the earliest cell types to be exposed to the virus.
1.Introduction
Based on the study of natural correlates of protection against
HIV infection, the overall outcome of disease may depend
on the host’s capacity to control the extent of inﬂammation
and preserve systemic integrity by constraining immune
activity to mucosal tissues, where viral exposure occurs.
There, DCs are one of the earliest cell types to be exposed
to the virus and present an inherent capacity to orchestrate
a homeostatic balance between tolerance and protection
[1–4]. It is likely that the incapacity to keep a balance in
these homeostatic processes will promote inﬂammation and
lead to disease progression [5]. In contrast, the capacity to
maintainimmune homeostasisatmucosalsiteswillprobably
allow for better control of HIV-infection. The general eﬀects
of HIV-infection and disease on DC populations have
been recently reviewed [1–4] and are beyond the scope
of this work. This perspective review will focus on the
potential impact of DCs on HIV-related B-cell disorders and
responses.
Although the vast majority of HIV-infected individuals
can now achieve and maintain viral suppression with
modern antiretroviral therapy (ART), their life expectancy
remains much shorter than the general population and they
continue to be at much higher risk for non-AIDS-associated
diseases commonly associated with aging. B lymphocyte
dysregulations are often observed during HIV infection
(reviewedin[6]),contributingtoabnormallevelsofimmune
activation and inﬂammation that may drive these clinical
events. Given that the requirements of B-cell populations
diﬀer according to their status and stage of diﬀerentiation,
theyarelikelytobeaﬀecteddiﬀerentiallybytheHIVcontext,
a process reﬂected by events such as polyclonal activation,
breakage of tolerance, altered subpopulation dynamics,
exhaustion, and loss of the capacity to generate and maintain
memory. All of which contribute to a global impairment of
the humoral immune compartment, leading to deﬁciency in
the generation of eﬃcient anti-HIV responses.
Although the mechanisms involved in the triggering and
progression of HIV-related B-cell disorders remain largely2 Clinical and Developmental Immunology
unknown, it has been suggested that they result from high
viremia and an impaired CD4+ T cell compartment [6].
However, ART does not appears to fully restore the B-
cell compartment since autoimmune manifestations and
malignancies are still detected despite recovery of CD4+ T
cell counts and suppression of viral replication by ART.
In fact, the B-cell disease seems to progress and diﬀer in
subtype depending on the level of CD4+ T cell compartment
alteration/reconstitution [6]. The fact that some B-cell
disorders can persist despite successful ART and in absence
of apparent disease progression [6–10] suggests that factors
other than and/or complementary to viral load and CD4+ T
cells may contribute to HIV-related B-cell dysregulations. It
is unlikely that they result from direct infection of B cells.
Indeed, despite the fact that HIV has been shown to replicate
in CD40-stimulated B cells in vitro [11–13], the virus has
not yet been shown to infect or replicate in B cells in vivo
[6, 11–17]. Moreover, although Epstein-Barr virus (EBV)
has been reported to be involved in the AIDS-related B-
cell dysregulations leading to lymphomas, only 30–40% of
the complications are EBV related and more so the result of
chronic stimulation [18].
DCs are involved in the outcome of B-cell develop-
ment, diﬀerentiation and survival, in T-dependent and T-
independent manners, mainly through production of the
tumournecrosisfactor(TNF)familymembersBlymphocyte
stimulator (BLyS/BAFF) and a proliferation-inducing ligand
(APRIL) [19, 20]. BLyS is involved in transitional immature
(TI) B-cell survival and ontogenesis, and both BLyS and
APRIL have been shown to promote B-cell diﬀerentia-
tion by inducing molecular events characteristic of class
switch recombination (CSR) leading to secretion of isotype
switched Ig when in conjunction with signals delivered via
the B-cell receptor (BCR) or Toll-like receptors (TLRs) [21–
24].
Interestingly, we have recently demonstrated that BLyS
overexpressing myeloid DCs (mDCs) are present in the
blood of HIV-infected rapid and classic progressors, as soon
as in the acute phase of infection and persisting despite
successful therapy. Accordingly, these individuals present
B-cell dysregulations favouring the overall inﬂammatory
burdenandpreventingeﬀectiveviraleradication.Incontrast,
HIVelitecontrollershadnormallevelsofBLySexpressionon
their blood mDCs, and presented an unaltered blood B-cell
compartment. These observations suggest that the extent to
which HIV disease progression is controlled may be linked
to the integrity of the DC compartment and to its capacity to
orchestrate B-cell population dynamics and responses.
2. Observations withthe HIVTransgenic
(HIV-Tg) MouseSystem
EarlydatasupportingthehypothesisthatDCsareinvolvedin
the dysregulation of the B-cell compartment in the context
of HIV, were obtained with HIV-Tg mice expressing the
coding regions for proteins Rev, Env, and/or Nef of HIV-
1, under the control of the human CD4 promoter, and
mouse CD4 enhancer, which drive expression in CD4+ T
cells, macrophages and DCs [25–27]. HIV-Tg mice develop
a disease, which is dependent on nef and comparable to
manyaspectsofhumanAIDS[25,26].Intheseanimals,total
B-cell numbers were increased in lymph nodes (LN) and
spleen, the latter presented a particularly enlarged marginal
zone (MZ) [25, 26, 28]. Polyclonal B-cell activation was
reﬂected by hyperglobulinemia and accumulation of anti-
dsDNA autoantibodies in serum, as well as by spontaneous
hyper-reactivity in vitro [28]. The capacity to generate
germinal center (GC) reactions and mount matured anti-
body responses following immunisation was also severely
impaired in these animals [28]. Soluble Nef has been shown
to penetrate B cells and/or to be propelled via macrophage
extensions, suppressing Ig CSR by blocking CD40 signalling
and thus impairing the capacity of generating high aﬃnity
T-dependent memory B-cell responses [29, 30]. However,
B cells enriched from the spleen of HIV-Tg mice behaved
similarly to those of littermate controls by CSR in response
to anti-CD40 stimulation in vitro, suggesting that soluble
Nef was not mainly responsible for the impaired capacity
of these animals to generate isotype-switched Ig following
immunisation [28]. Whether propelling of soluble Nef
operates in the context of DC collaboration with B cells
remains to be established. The direct eﬀects of Nef on
B cells are likely to vary with the status and activation
requirementsofthediﬀerentB-cellsubpopulations,andDCs
may modulate these responses accordingly.
Therefore, as reported in humans, HIV-Tg mice present
polyclonal B-cell activation and breakage of tolerance as well
as an impaired capacity to generate high aﬃnity adaptive
humoral responses. Interestingly, CD11c+CD11bhi mDCs
from HIV-Tg mice accumulated at entry points of secondary
lymphoid organs (SLO) [31], in the LN subcapsular sinus
as well as in the MZ of the spleen [28, 32]. Also, mDCs
agglomerated among IgMbright plasma cell foci in the red
pulp adjacent to the MZ. The fact that blood derived
immature mDCs are the primary cells that eﬃciently capture
and transport particulate Ag to the splenic MZ, where they
provide signals to Ag-speciﬁc MZ B cells [33, 34], suggest
that their accumulation at such sites likely contributes to the
enlargement of the MZ B-cell population, as well as to the
polyclonal activation and breakage of tolerance observed in
HIV-Tg animals [28]. This most possibly involves delivery
of “altered and/or excessive” contact events and/or B-cell
growth factors, such as BLyS, as mDCs from HIV-Tg mice
were shown to be altered in their numbers, phenotype and
stimulatory functions [32].
BLyS overexpressing mice also present enlarged splenic
MZ, B-cell hyperactivity and autoimmunity [35] ,ap h e -
notype also shared by autoimmune-regulatory-(AIRE)-
deﬁcient mice, in which BLyS levels are elevated in serum
and overexpressed by peripheral blood CD11c+ DC and
stimulated bone marrow-derived DCs [36, 37]. Of note,
AIREisinvolvedinregulationofSTAT1signalling,apathway
shown to be used by the HIV Nef protein to promote a
proinﬂammatory phenotype by human monocyte-derived
macrophages [38, 39] and likely in modulation of the over-
expression of TNF-α by human monocyte-derived DCs [40].
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the serum of HIV-infected patients [41]. Furthermore, Nef
was reported to penetrate DCs and to alter DC maturation
and function, and to induce distinct cytokine/chemokine
secretion patterns [1]. Thus early HIV-released products
such as Nef may play an important role in modulating DC
phenotype, likely inﬂuencing the outcome of B-cell disease
progression.
Several other HIV products are also likely to inﬂuence
DCs. Indeed, HIV ssRNA, gp120, and Tat are considered
to be major modulators of cellular activation via microbial
pattern recognition receptors (PRR), including TLRs, which
DC populations express in a wide range, and which prior
engagement leads to subversion of the immune response
[42]. Interestingly, HIV-ssRNA is recognised by TLR7, which
signalling was shown to regulate human monocyte-derived
DC-dependent B cell responses through upregulation of
BLyS [43]. As such, both mDCs and plasmacytoid (pDCs)
enriched from the blood of primary HIV-infected individ-
uals were found to be hyperresponsive to TLR7 agonists
and produced high amounts of cytokines and chemokines
upon stimulation [44]. HIV-gp120 has also been shown
to mediate B-cell polyclonal activation, driving CSR in a
BLyS-dependentmanner[45].Altogether,theseobservations
support a role for DCs and BLyS in triggering and driving B-
cell dysregulations in the context of HIV.
3. HIVDiseaseProgression:Role for BLyS
OverexpressingmDCs in DrivingB-Cell
Dysregulations
In recent longitudinal studies involving HIV-infected indi-
v i d u a l sw i t hd i ﬀerent rates of disease progression, we have
shown that mDC frequencies were reduced in the blood
of rapid and classic progressors, as soon as in the acute
phase of infection and persisting throughout the course of
disease despite successful therapy [46]. The low blood levels
of mDCs correlated with increased serum levels of DC-
tropic chemokines CCL2, CCL19, and CCL20, suggesting
drainage to peripheral sites [47]. Most importantly, our
studies have revealed increased levels of BLyS expression
in the plasma and on the surface of these blood mDCs
[7]. Therefore, mDCs may play a major role in per-
petuating B-cell dysregulations, as they overexpress BLyS
and are recruited to peripheral sites. Furthermore there
might be a pressure towards monocyte-driven diﬀerentiation
into BLyS overexpressing mDCs, since BLyS overexpressing
CD11c+CD14+CD16− monocytes, precursors of DCs [48,
49], were increased in the blood of chronically infected
rapidandclassicprogressors[7,46].Interestinglythemurine
analogue of the CD11c+CD14+CD16− population (Gr-1hi
monocytes) are linked to the formation of “Tip-DCs” which
are a source of inﬂammatory cytokines and TNF [49].
Consistently, in HIV progressors, B-cell dysregulations
were found throughout followup and were accompanied by
the increased frequency of a population presenting features
shared by both transitional immature (TI) and circulating
MZ-like B cells, bearing a CD1c+CD21loIgMhiCD10+CD27+
p h e n o t y p e ,w h i c hw eh a v et e r m e d“ p r e c u r s o r / a c t i v a t e dM Z -
like” B cells [7]. Of course, the human MZ is a complex
heterogeneous niche, and MZ-like B cells have been shown
to recirculate in humans and are not restricted to the spleen
[50]. Further characterization is thus required to identify
the exact nature of these B cells. Nevertheless, we believe
these cells represent a “ﬁrst-line” B-cell population that
increases in the context of inﬂammatory conditions such
as in HIV infection. These ﬁndings are in line with the
recentlydescribeddefectsofIgM+ “memory”Bcellsreported
for some HIV-infected individuals [6]. TI B cells have been
f o u n dt ob ee l e v a t e d[ 51] and to preferentially give rise to
MZtypeBcellsinconditionsoflymphopeniaassociatedwith
pathology [52]. The fact that TI B cells are hyperresponsive
to BLyS [21] and are increased in the blood of HIV-infected
patients with advanced disease [53], suggests that mDC
expressing high levels of BLyS may contribute to increased
survival of TI B cells and favoured selection into a MZ-like
“ﬁrst-line” B-cell pool [54].
These observations suggest that the DC-mediated B-
cell dysregulation process we are proposing would likely,
although not solely, aﬀect immature and “ﬁrst-line” B-
cell populations. Given their location in lymphoid organs
and mucosal-associated structures, “ﬁrst-line” B-cell popu-
lations are highly inﬂuenced by DC and constitute early T
cell-independent defence against invading pathogens [22].
Also, given their frequent auto-reactive and cross-reactive
repertoires and their relative hyperactivity, these populations
are often found in pathologic conditions associated with
infections, autoimmunity and lymphomas [21, 22]. This
likely involves chronic stimulation and excessive delivery of
survival signals [16, 21, 22, 55], which altogether may over-
come mechanisms of peripheral tolerance and homeostasis.
The aberrant expression of BLyS and/or its receptors is often
linked to B-cell autoimmunity and malignancies [21, 56–
58]. As such, anergic auto-reactive B cells were shown to
evade negative selection when provided with excess BLyS
[56, 57]. Recently, excess BLyS was found to be involved in
the breakdown of B-cell tolerance in Sj¨ ogren’s syndrome,
favouring expansion of TI and MZ-like B cells [21]. This
is reminiscent of events observed during the course of
HIV infection, and is in line with correlations between the
elevated blood levels of autoreactive antibodies (Abs) and
high levels of BLyS expression in the plasma and on the
cell surface of blood monocytes in HIV-infected individuals
[59, 60].
Altogether,theaboveobservationsareconsistentwiththe
model by which, in the context of HIV disease progression,
the high turnover of peripheral DCs may promote the
recruitment of BLyS overexpressing monocytic precursors
and mDCs, likely contributing to an inﬂammatory milieu
and modulating the outcome of B-cell responses (Figure 1).
However, as to whether this process is regulated by the
host response and/or modulated by direct and indirect
viral eﬀects, remains to be established. Likely explanations
involve factors such as HIV-products, excessive apoptosis
and release of auto-Ag, as well as products from microbial
translocation resulting from breakage of mucosal integrity.
Interestingly, levels of products from microbial translocation
such as LPS, LBP, and sCD14 were elevated in the blood of
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overexpressing mDCs and of “precursor/activated MZ-like”
B cells [7, 46].
4. Control of HIV DiseaseProgression:
Preservation of BLyS Expression Status by
mDC FavoursEfﬁcientB-Cell Responses
In contrast to that observed in rapid and classic HIV
progressors, blood mDC levels and BLyS expression status
were unaltered in HIV elite controllers [7, 46]. However,
monocyticDCprecursorsofaCD11c+CD14+CD16+ pheno-
type, whose murine analogs are thought to settle peripheral
organs in steady-state conditions [48, 49], were found to
be signiﬁcantly increased in their blood [46], suggesting
high turnover in absence of excessive inﬂammation. Also,
although the blood B-cell compartment remained unaltered
in HIV elite controllers, their blood level of mature MZ-
like B cells was lower when compared to that in both
rapid and classic progressors, as well as to healthy donors
[7]. This suggests that recruitment of this “ﬁrst-line” pop-
ulation to peripheral sites may be beneﬁcial to the host
and “control” process. Although our observations in HIV
elite controllers may reﬂect early stages of malfunction,
we rather favour the view by which HIV-mediated disease
control may be an active process involving DC populations,
preventing B-celldysregulation and favouring the generation
of ﬁrst line as well as eﬀective broadly neutralizing anti-
HIV antibody responses. In line with this, the capacity of
some HIV-infected individuals to produce potent broadly
neutralizing antibodies constitutes a good correlate of prog-
nosis against disease progression [61]. Indeed, the relatively
poor antigenicity and silenced immunogenicity of HIV-Env
neutralization epitopes preclude the induction of eﬃcient
neutralising Abs in most HIV-infected individuals [62].
Needlesstosaythatunderstandingthegenerationofsuch
antibodies has become pivotal to the pursue of HIV vaccine
research [63].
Given that mucosal DC populations are gate-keepers of
peripheral integrity and amongst the ﬁrst to be involved in
the battle against HIV, it is likely that they inﬂuence the
outcome of mucosal B-cell responses against the virus. IgA
is the most abundant mucosal Ig and aids several functions
including immune-mediated exclusion of both pathogenic
and commensal microorganisms [22, 64]. High levels of
mucosal HIV-speciﬁc IgA have been found in highly exposed
persistently seronegative (HEPS) individuals [65], whereas
mucosal HIV-speciﬁc IgA responses are rather low in HIV
progressors [6]. Although the issue of “protection” conferred
by mucosal HIV-speciﬁc IgA remains controversial [65], in
many studies these Igs have been found to neutralize HIV
infectionandinhibitviraltranscytosisinvitro.Arecentstudy
on HIV-gp41-speciﬁc mucosal IgA, produced by cervical
B cells from HEPS individuals, demonstrated evidence for
hypermutation and aﬃnity maturation [66]. These observa-
tions based on natural control/immunity versus HIV suggest
that eﬀorts to develop an eﬀective vaccine against HIV
should consider soliciting HIV-speciﬁc mucosal IgA produc-
tion. In support of this are the recent ﬁndings by Bomsel
et al. demonstrating that mucosal IgA and IgG, elicited
through mucosal vaccination with HIV-1 gp41 subunit
virosomes in nonhuman primates, prevented systemic inva-
sion following vaginal simian-HIV challenge, by blocking
transcytosis and by mediating antibody-dependent cellular
cytotoxicity (ADCC) [67]. Importantly, these animals lacked
serum neutralizing antibody activity, highlighting the role of
eﬀector antibodies at the mucosal portal of entry, and their
importance in preventing dissemination of HIV infection
[68]. In humans, the Thai RV144 vaccine trial has been
raising some hope. Although the nature of the immune
responses responsible for the modest protection conferred
(31%) have yet to be unravelled, it appears that the RV144
vaccine regimen may have elicited transient protective B-
cell responses, which nature in terms of generation and
eﬀector mechanisms has become critical to deﬁne, and
appears to involve short-lived antibody responses viewed to
block HIV transmission at mucosal surfaces [69]. However,
in light of the protection correlates data released at the
AIDS Vaccine 2011 meeting in Bangkok, (J. Kim, B. F.
Haynes and colleagues), high levels of plasma Env IgA,
most probably monomeric, correlated with a 54% increased
risk of infection. This is in line with our ﬁndings showing
that rapid and classic HIV progressors presented hyper-
IgA in their serum when compared to slow progressors
and elite controllers [7]. Moreover, the fact that BLyS levels
were increased in the blood and on the surface of mDC
in rapid and classic progressors may have favoured serum
hyper-IgA production. Indeed, overexpression of BLyS in
Tg mice has been shown to favour monomeric hyper-IgA
CSR by spleen MZ B cells [70], a population known to
present enhanced IgA CSR potential [71], and which we
have shown to be activated and increased in the blood
of rapid and classic HIV progressors [7]. Nevertheless,
production of serum and mucosal IgA appear to follow
diﬀerent circuits, and requirements may diﬀer depending
on the sites of induction, the immunomodulatory milieu,
and B-cell populations responding [72]. It is, therefore,
possible that high levels of monomeric IgA in the blood
may increase risk of infection and systemic invasion, whereas
the production of dimeric IgA at mucosal sites may confer
protection. Unfortunately, there were no mucosal samples
in the RV144 trial to assess mucosal dimeric Env IgA levels,
which we would predict may constitute better correlates of
protection.
Again, based on these observations, our model would
suggest that systemic and mucosal BLyS expression status,
likely contributes to the modulation of B-cell responses
against HIV. On one hand, BLyS expression patterns at
mucosal ports of entry may promote mucosal IgA and
also IgG, viewed to block systemic invasion by the virus.
On the other hand, the incapacity to control these levels
and constrain this immune activity to mucosal sites may
allow breaching systemic integrity and perpetuating disease
(Figure 1).
5. The Importance of DCs atMucosal Sites
DCs are involved in maintaining a balance between tolerance
versus protective immunity at both the innate and adaptiveClinical and Developmental Immunology 5
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Figure 1: The implication of BLyS/BAFF expression status in the modulation of HIV-speciﬁc reponses. Control of HIV infection is reﬂected
by the capacity to regulate BLyS/BAFF expression status at mucosal sites, where the main battle against HIV takes place, promoting eﬃcient
HIV-speciﬁc B- and T-cell responses, viewed to block systemic invasion by the virus. In contrast, breaching of systemic integrity and
progression of HIV infection is reﬂected by the incapacity to control BLyS/BAFF levels at mucosal sites, leading to dysregulated B- and
T-cell responses, impairing the generation of highly protective HIV-speciﬁc immunity.
levels, which process is pivotal at mucosal sites, where
immune homeostasis processes warrant peripheral integrity,
and where the main battle with HIV takes place [1–
4]. Recent studies have demonstrated the importance of
cross-talk between epithelial cells and mDC populations in
maintenance of a homeostatic balance of regulatory versus
inﬂammatory responses at the mucosal level [73–75]. In the
murine gut, two mDC populations have recently been given
importance, the CD103+ and CD103− mDC populations
which derive from distinct precursors and are found in the
mucosal associated lamina propria and draining lymphoid
organs [76, 77]. Murine gut lamina propria CD103+ mDC
are known to support the generation and retention of IgA-
producing B cells in the lamina propria through retinoic
acid (RA) production [78]. Also, the tolerogenic capacity
to modulate CD4+ Tr e g u l a t o r y( T r e g )l y m p h o c y t e si sc o n -
ferred by CD103+ mDC through transforming growth factor
(TGF)-β and RA-dependent mechanisms [73]. On the other
hand, the CD103− mDC population was shown to produce
higher levels of proinﬂammatory cytokines and generate
protective immunity [48], promoting the diﬀerentiation
of CD4+ Tm u c o s a le ﬀector lymphocytes [79]. Creating
imbalance in these mDC populations by favouring CD103−
mDC reconstitution leads to experimental-induced colitis in
aT N F - α-dependent manner [76, 77]. Analogous mucosal
mDC populations have been described in the human gut
[73] and more recently in the human lung, where they
havebeenshowntodiﬀerentiatefrommonocytepopulations
[80]. Based on these observations, it is tempting to speculate
that in the context of HIV infection, the incapacity to keep
a balance in homeostatic mucosal mDC populations, may
allow for increased “proinﬂammatory” mDC, possibly over-
expressing BLyS, to accumulate at mucosal sites, where they
contribute to the imbalance of T regulatory/eﬀector ratios
and modulate the outcome of mucosal B-cell responses.
Although IgA+ plasma cells are generated mainly in the
mucosal-associated lymphoid tissue (MALT) through a T-
dependentmechanism,IgA+ celldiﬀerentiationhasalsobeen
shown to be modulated in the MALT in a T-independent
fashion through factors such as RA and cytokines such as
BLyS and APRIL produced by mDCs. Also, mDCs were
found to support T-independent IgA class switch recombi-
nation in human lamina propria via production of APRIL
[22, 64]. Interestingly in mice, both conventional B2 and
ﬁrst-line IgM+ peritoneal B1 cells, have been shown to
migrate directly to the gut lamina propria and diﬀerentiate
into IgA producing cells [64], through help provided by
lamina propria mDCs. Importantly, TLR-mediated epithelial6 Clinical and Developmental Immunology
cell:DC cross-talk at the level of human tonsillar crypts was
shown to orchestrate B-cell CSR through modulation of
BLyS levels via epithelial cell secretion of thymic stromal
lymphopoietin (TSLP) [75]. Work by Fontenot et al. [81]
demonstrated that HIV induces human genital mucosal
epithelial cells to produce TSLP, activating mDCs, which in
turn promote HIV-1 replication in CD4+T cells. Further-
more, in rhesus macaques, increased TSLP expression was
found to be concurrent with viral replication in the vaginal
tissues within the ﬁrst 2 weeks after vaginal SIV exposure.
Therefore, these studies suggest that levels of TSLP involved
in the cross-talk between mucosal epithelial cells and mDCs
may contribute to modulating BLyS levels, and this may
be important in modulating the fate of HIV infection in
mucosa, and the outcome of disease progression.
Based on these observations, it is reasonable to think that
the incapacity to keep a balance in homeostatic epithelial
cell:DC cross-talk processes, which is likely to occur in
individuals who progress with HIV infection, will promote
inﬂammation and lead to disease perpetuation. In contrast,
the capacity to maintain immune homeostasis at mucosal
sites may allow for better control of immune responsiveness
and HIV infection. This view is consistent with a report
showing that early prevention of macrophage inhibitory
protein (MIP)-3α (CCL20) production in the genital tract
of SIV-susceptible female macaques prevented excessive
recruitment of pDC and mDC populations, establishment
of an inﬂammatory milieu and infection, despite repeated
intravaginal exposure to high doses of SIV [82]. Further-
more, studies of SIV infection in nonpathogenic animal
models have shown that their control of disease progres-
sion appears linked to better management of the aberrant
immuneactivationbyearlyonsetofanti-inﬂammatoryIL-10
production and T regulatory activity. Mucosal Th17 eﬀectors
are the main targets for HIV/SIV in the gut and massive
depletionofthesecells[83–86]contributestothebreakageof
integrity of the mucosal barrier and microbial translocation
from the gut, characteristic of pathogenic infections [87].
Fewer, Th17 eﬀector target cells were generated in non-
pathogenic than in pathogenic SIV infections [88], a process
linked to a low type I interferon- (IFN-) gene proﬁle and
low TLR7-signalling [89]. Interestingly, both type I IFN-
and TLR7-signalling have been shown to be involved in
regulation of BLyS expression patterns by DC populations
[43, 90].
6. Role of DC in ModulatingB-Cell
Effector/RegulatoryResponsesintheContext
of HIV
The inﬂuence of DC in the outcome of B-cell responses
against HIV may modulate the outcome of CD4+ T-cell
eﬀectors/targets for the virus. Indeed, there is an increasing
body of experimental evidence demonstrating the role of B
cells in regulating the development, proliferation and main-
tenance of CD4+ eﬀector, memory as well as regulatory T cell
populations,throughbothcontactand/orcytokinemediated
eﬀector/regulatory functions [91, 92]. The increased lym-
photoxin “eﬀector” to IL-10 “regulatory” B-cell ratio was
recently demonstrated in the pathophysiology of multiple
sclerosis (MS), promoting proinﬂammatory T cell eﬀector
functions [93]. MS patients treated with a single course of
Rituximab, a monoclonal antibody that selectively targets
and depletes CD20+ B lymphocytes but not plasmablasts,
presented lower inﬂammatory brain lesions and clinical
relapses,characterisedbythereductionineﬀectorTlympho-
cyteinﬁltratesaswellasdecreasedproinﬂammatoryTh1and
Th17 responses [94].
Episodic depletion of B cells is an eﬀective therapy for
several T cell-mediated autoimmune diseases by promoting
the emergence of regulatory B-cell populations that will
hopefully prevent the reactivation of remaining autoreactive
T cells [91]. The fact that at low concentrations BLyS was
shown to favour IL-10-production by murine splenic MZ
“regulatory” B cells, whereas elevated BLyS concentrations
rather promoted MZ B-cell activation and diﬀerentiation,
suggests that BLyS may play an important role in modulating
the nature of B-cell functions and subsequently the outcome
of Treg/T eﬀector balance [95]. As such, blocking of BLyS,
which has been used as a therapeutic target in clinical trials
for the treatment of autoimmune disorders such as systemic
lupus erythematosus (SLE) [58], may also be eﬃcient in
modulating this balance. In this view, decreased eﬀector
CD4+ T cell functions and increased regulatory CD4+ T
cell functions were observed following treatment of NOD
mice (model for type I diabetes) with the B-cell maturation
antigen (BCMA)-Fc construct, which blocks BLyS-mediated
survival signals for B cells. In a collagen-induced model
of rheumatoid arthritis, BLyS overexpression was shown to
promote the expansion of Th17 eﬀector cells, and BLyS gene
silencing inhibited DC driving of Th17-cell diﬀerentiation
in vitro [96]. These observations suggest that DCs may
inﬂuence T cell diﬀerentiation and eﬀector target CD4+ T
cell availability for HIV in a BLyS-mediated manner either
directly and/or indirectly via modulation of B-cell functions.
7. Concluding Remarks
The extent to which HIV disease progression is controlled
may be linked to the integrity of the DC compartment and
BLyS expression status, and to its capacity of orchestrating
B-cell population dynamics and responses. This may be best
achieved at mucosal sites, where DC populations present
an inherent capacity of modulating the balance between
tolerance and protection, and are amongst the earliest cell
types to be exposed to the virus. It is, therefore, likely that
they inﬂuence mucosal B-cell responses against HIV, which
in turn modulate the outcome of CD4+ Tc e l le ﬀectors,
prime targets for the virus. The early assessment of BLyS
levels as well as DC and B-cell population statuses have great
prognostic value in predicting the clinical course of HIV
infection. This should be borne in mind in the design of
future preventive vaccines, which should aim at inducing
ﬁrst line as well as adaptive mucosal B-cell responses to
block systemic invasion by the virus at the initial site of
exposure. Therapeutic approaches viewed to control BLyS
levels may also be promising to reduce both HIV target cells
and systemic immune activation that are the hallmarks ofClinical and Developmental Immunology 7
HIV disease progression and AIDS-associated diseases such
as cancers, autoimmune, and cardiovascular disorders.
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